The monoclonal antibody CT-P13 is a biosimilar of infliximab. Owing to a lack of confidence amongst gastroenterologists in using this drug for patients with IBD, a prospective, multicentre study was conducted to examine the safety, efficacy and immunogenicity of CT-P13 for the treatment of Crohn's disease and ulcerative colitis (n = 210). The investigators found that CT-P13 induced and maintained high clinical remission and response rates in IBD. However, patients with previous infliximab exposure showed markedly decreased responses and were more prone to allergic reactions.
References
Gecse, K. B. et al. Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: A prospective, multicentre, nationwide cohort. J. Crohns Colitis 10, 133–140 (2016)
Rights and permissions
About this article
Cite this article
Dickson, I. CT-P13: a safe and effective treatment for IBD. Nat Rev Gastroenterol Hepatol 13, 122 (2016). https://doi.org/10.1038/nrgastro.2016.28
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2016.28